



Generali Employee Benefits Network at a glance

Journey Together #WeSpeakYourLanguage

April 2021



01


Our presence and vision

Building a sustainable future, together.



Generali Employee Benefits (GEB) Network

Leading the change in the EB world: YE 2020 Integrated Figures




One GEB team ensuring worldwide service

203 people, 3 regional hubs and 12 office locations



Protecting your people, wherever they are

Covering 123 countries globally, together with our 139 Network Partners



■ GEB Network coverage

GEB Network Partners

- ✓ local insurers
- ✓ **top ranked** in their market
- ✓ recognized for their **outstanding expertise** and **high-quality services**
- ✓ specialists in the employee benefits sector.

Our promise: We focus on Lifetime Partner value

Key differentiators as assets for our Journey Together.



One point of contact,

dedicated and best-in-class service teams to simplify the customer journey



Regulated and global approach

to provide peace of mind and responsiveness across our extensive network



Technical/innovative mindset

to unlock new opportunities and answer evolving customer needs



Digital data and information-sharing

through value-added services and an ecosystem of partnerships

Focused expertise in supporting multinational corporations

02

Our solutions and services

Protecting your people, together.



Our employee benefits solutions

We take care of the risk while you increase your governance.

Lifecycle Pooling

Global

Adapting to the client's size and risk profile over time on the basis of premiums and countries included in the pool. This solution brings together the strength and simplicity of a Multiemployer pool mode for smaller pooled premiums and a Standalone pool mode for larger pooled premiums, which can be customised above certain thresholds.

Captive

Global

A Captive is a (re-) insurance company set up exclusively to insure or reinsure the risks of the group to which it belongs. It represents a strategic approach to the management of a company's insured benefit plans, and it offers attractive ways to govern, finance and deliver competitive employee benefits packages with full transparency and control.

Global Underwriting

Global

Enabling a proactive funding strategy to optimise the financial and information flow of local employee benefits plans. Global underwriting also offers enhanced terms & conditions, as well as negotiated centrally plus upfront pricing optimisation according to combined ratios per country and per coverage.

Reinsurance Only

Local


Supporting our local network partner to service and cover the subsidiaries and branches of large multinational corporates. Leveraging their local UW capabilities and supporting them to service multinational corporations, even without international solutions.

Health & Wellbeing Services

Dedicated H&W team, interactive digital dashboards and strong partnerships

Global medical claim dashboard

Provides global and country-specific views of trends and cost drivers in 40 countries covering 90% of the GEB portfolio



Health Resource Center

Online tools, services, communication kits and partnerships for digital healthcare services




Client Data Centre

24/7 access for clients and brokers to data, reports and dashboards


One point of reference

- ✓ Online dashboard of historical data
- ✓ Updated quarterly
- ✓ Interactive
- ✓ Downloadable opportunities
- ✓ Global, regional and local




COVID-19 Resource Centre

All information is accessible at geb.com/COVID-19.



- COVID-19 resources on GEB.com
- Updated on an ongoing basis
- Links to global health resources including WHO dynamic maps, public health sites
- Network partner T&Cs pertaining to Covid-19
- Region-specific detail including local health updates, ministry of health announcements, announcements from local hospital authorities



COVID-19

Being a GEB Partner to our clients is for us of the utmost importance and, today more than ever, it means building trust and giving clients the assurance of the emergency. With the outbreak of the COVID-19 epidemic, we have immediately taken action to make sure you are informed as to what we are doing as a Network for you and your employees.

This sector is intended to be **informative** and **your practical advice** on COVID-19 **not for enable employees and multinational companies** at our the world.

GEB Network is highly committed to sharing **updated information** on local practices of managing COVID-19 outbreak and actively supporting members.

Find in the dedicated pages how GEB Network is responding to COVID-19 locally and which services are available for your employees.

For further questions, please contact geb@geb.com.

[View updated on the World Health Organization](#)

WHO Regional Office COVID-19 Dashboard
Data last updated: 2020-05-29 13:29:03:07

Region	New cases	Confirmed cases	Deaths
Global	194,917	5,704,736	357,736

Global, as of 7:03pm CEST, 28 May 2020. There have been 5,704,736 confirmed cases of COVID-19, including 357,736 deaths, reported to WHO.

GEB Network supporting materials and useful links

- [Remove advice on COVID-19 for mobile employees - 28 May 2020](#) by GEB Awareness
- Register advice on medical information and action recommendations regarding the COVID-19 epidemic.
- [Information and updates by the World Health Organization](#)
- World Health Organization website dedicated to the COVID-19 outbreak with situation reports, travel advice, medical recommendations and an updated world map with the spread of COVID-19.
- [COVID-19 situation updates by Centers for Disease Control and Prevention](#)
- Centers for Disease Control and Prevention website dedicated to the COVID-19 outbreak with useful tips on how to protect yourselves and to spot the symptoms. Recently used questions, travel advice and check-ups.



COVID-19 Health Bulletin

Keeping safe Simple steps for you and your family

Following is information drawn from public health sources on how to protect yourself and others from the COVID-19 virus.

Since there is no vaccine or drug therapy currently available, avoiding exposure and preventing spread are the best ways to keep everyone safe. Here are 6 steps you can take immediately to avoid exposure and prevent spread:

- 1** Maintain your social distance from others. If you have to go out for essential activities, keep at least 2 meters (approximately 6 feet) between yourself and others to prevent inhalation of droplets that can be shared by talking, sneezing or coughing.
- 2** Wash your hands with soap and water for at least 20 seconds. After this, use an alcohol-based hand sanitizer to continue to protect your hands from virus.
- 3** Avoid touching your eyes, nose, and mouth all of which are potential points of entry for the virus.
- 4** Practice good respiratory hygiene by coughing or sneezing into your bent elbow or a tissue; dispose of the tissue immediately in a sealed trash bin.
- 5** If you develop symptoms seek medical advice but call your doctor first. Calling your doctor or contacting a telemedicine provider if this is available to you will allow the health-care professional to direct you to an appropriate facility and help to prevent further spread of the virus.
- 6** Know when and how to wear a mask. Do wear a mask if you're coughing or sneezing, or if you're helping to care for someone who is sick.

Keep informed and up to date by following instructions and guidance from the WHO, the CDC, your local government and health authorities.

GENERALI
Employee Benefits Network

Source: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/behavioural-advice>

COVID-19 Vaccine Bulletin

'Find out more at geb.com/COVID-19.

An informational piece on COVID-19 vaccines updated on a monthly basis; developed in collaboration with Granite Management, providing:

- ✓ Updates on virus variants
- ✓ Updates on approved vaccines and those in Phase 3 clinical trials
- ✓ Impact on employers
- ✓ What employers can do now

COVID-19 Vaccine Update

February 2021

February Updates

Growing threat of COVID variants

The variant appears to include mutations that could increase the risk of infection in people who have been vaccinated. Additional mutations observed in hospitalized patients in the United States and Europe.

There are concerns that the vaccine currently approved may not be as effective against all of the new variants. Research is also being done to see if the vaccine is more effective for certain and related to cell targeting. The extent of these concerns, particularly for the high-growth variant, will continue to be updated as more data becomes available, including regarding transmission and the effectiveness of other new variants.

It is now believed that the vaccine will be used to help reduce the risk of severe illness and hospitalization. While it is not yet clear how long the vaccine will last, it is expected that the vaccine will be used to help reduce the risk of severe illness and hospitalization. It is also expected that the vaccine will be used to help reduce the risk of severe illness and hospitalization.

Emerging variants and notable mutations

Following a high level of concern, the World Health Organization (WHO) has declared the B.1.1.7 variant a Variant of Concern (VOC). The B.1.1.7 variant is a highly contagious and transmissible variant, which may be more infectious and more effective for the new variant COVID-19, which may also be 50% more effective than the original COVID-19 virus.

B.1.1.7 Variant (first identified in UK)

- Identified in 90 countries, according to the WHO, this variant is the most common COVID-19 variant, and is spreading rapidly. It may also be 50% more effective than the original COVID-19 virus.
- Vaccine efficacy: There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy.

B.1.351 Variant (first identified in South Africa)

- Identified in 20 countries, this variant has been shown to be more infectious and more effective for the new variant COVID-19, which may also be 50% more effective than the original COVID-19 virus.
- Vaccine efficacy: There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy.

B.1.1.28 Variant (first identified in Brazil)

- Identified in 12 countries and is spreading in over 80% of COVID-19 cases. This variant has been shown to be more infectious and more effective for the new variant COVID-19, which may also be 50% more effective than the original COVID-19 virus.
- Vaccine efficacy: There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy. There is a significant concern over vaccine efficacy.

Vaccine rollout across the globe

Vaccine rollout continues to proceed steadily across the globe. As of February 1, 2021, over 1 billion doses of COVID-19 vaccine have been administered globally. The United States has the highest number of doses administered, followed by the United Kingdom, Germany, and France.

% Population vaccinated by country

Country	Numbered	Percentage
USA	100.0%	100.0%
UK	99.7%	99.7%
Germany	99.7%	99.7%
France	99.7%	99.7%
Spain	99.7%	99.7%
Italy	99.7%	99.7%
Canada	99.7%	99.7%
Japan	99.7%	99.7%
South Korea	99.7%	99.7%
China	99.7%	99.7%
India	99.7%	99.7%
South Africa	99.7%	99.7%
Brazil	99.7%	99.7%
Israel	99.7%	99.7%
Sweden	99.7%	99.7%
Denmark	99.7%	99.7%
Norway	99.7%	99.7%
Finland	99.7%	99.7%
Poland	99.7%	99.7%
Czechia	99.7%	99.7%
Slovenia	99.7%	99.7%
Lithuania	99.7%	99.7%
Latvia	99.7%	99.7%
Estonia	99.7%	99.7%
Portugal	99.7%	99.7%
Spain	99.7%	99.7%
France	99.7%	99.7%
Germany	99.7%	99.7%
Italy	99.7%	99.7%
UK	99.7%	99.7%
USA	99.7%	99.7%

Summary of approved vaccines

APPROVED VACCINES

Vaccine name (Phase)	Comments
AZD1222 (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam
BBV-152 (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam
CoronaVac (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam
Sputnik V (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam
Novavax (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam
Moderna (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam
Pfizer (Phase 3)	• Authorized in Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, USA, Vietnam




Quarterly update on partners, solutions, services and people


Subscribe on geb.com to GEB Client & Intermediary Insights.



Topics



Videos



Articles



Thank you. We look forward to starting our Journey Together.

Marketing & Customer Experience

Contact us at MandCE@geb.com



Find out more at geb.com #WeSpeakYourLanguage

Disclaimer

"This information and communication is provided by Assicurazioni Generali S.p.A. – Luxembourg Branch ("The Company") having its registered office at 52, boulevard Marcel Cahen, L-1311 Luxembourg, Grand-Duché de Luxembourg. Assicurazioni Generali S.p.A. – Luxembourg Branch is the Luxembourg branch of Generali Assicurazioni S.p.A, a limited liability company under Italian law, having its registered office at 34132 Trieste, piazza Duca degli Abruzzi, 2 and incorporated under company number 00079760328. By using this Publication or downloading it, you agree, and will be deemed, to abide by the Terms and Conditions set forth hereunder.

The contents of this Publication are property of the Company. All rights are reserved to the Company. Part or all of the contents of this Publication cannot be copied, reproduced, transferred, uploaded, published or distributed in any way without the Company's prior written permission, except that the Company consents you to print extracts from these pages for your personal use only. The trademarks and logos displayed on this Publication are the property of the Company and of its subsidiaries (Generali Group) or of their respective owners. They cannot be used without the prior written consent of the Company.

The information in this Publication is provided in good faith by the Company which believes it to be accurate. This Publication is not intended to cover every aspect of the referenced benefit topics and the Company does not warrant its completeness or accuracy. This Publication is not designed to provide legal or other advice and readers should consult legal or financial advisors for counsel or international benefits matters. The information in this Publication is produced by both internal and external sources. The Company reserves the right to modify the said information and the functional and operational use specifications applying to the Publication as and when it chooses to do so, at its own discretion and with no forewarning. The Company will do its utmost to ensure that the information presented in the Publication fully conforms to the requisites of reliability, truthfulness and accuracy. However, the Company accepts no responsibility for any errors or imprecision in the content of the Publication resulting from circumstances that cannot be ascribed to the Company. The Company accepts no responsibility for the reliability, truthfulness accuracy and validity of any information in the content of the Publication which cannot be ascribed to the Company. Furthermore, the Company accepts no responsibility for any untoward consequences of brief or prolonged interruptions, delays or dysfunctions in the provision of the Publication service due to circumstances beyond the control of the Company. None of the information contained in the linked websites constitutes a recommendation, solicitation or offer by the Company or its affiliates to buy or sell any securities or other financial instruments or provide any investment advice or service; some information may be found on the linked websites as its publishing is required or recommended by law, regulations or provisions of self-regulatory codes. The information in this Publication may not be used, downloaded or imported abroad or by aliens where the provision, use, communication or dissemination thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory organisation or self-regulatory organisation or where the Company is not authorised to provide such information or services. Such information does not constitute or form part of, and should not be construed as an offer by or on behalf of the Company or an invitation to subscribe or purchase any securities in any countries, including in any foreign countries, including, without limitation, the United States of America or to any "U.S. Person" as defined in the "Regulation S" under the United States Securities Act of 1933 (Securities Act), as subsequently amended".